# Retatrutide: What It Is and What the Trials Show

Retatrutide is a man-made peptide that switches on three receptors at once, which is why it is called a triple agonist. This guide covers what that means, which receptor it acts on most strongly, what the trials measured, and what is still unknown. It is not approved anywhere, and is supplied for in vitro research purposes only.

- Source: https://www.australianresearchpeptides.au/articles/retatrutide-mechanism-and-trial-record
- Reading time: 4 minute read
- Published: 2026-08-19
- Updated: 2026-09-02
- Publisher: Australian Research Peptides

---

In vitro research purposes only.

Retatrutide is an experimental compound. It is not approved by any medicines regulator, anywhere, for any purpose. Everything below describes published research. Nothing here is a protocol, a dose or a recommendation, and material supplied by Australian Research Peptides is for in vitro research purposes only.

## What Is Retatrutide?

Retatrutide is a single man-made peptide that switches on three different receptors in the body.

A receptor is a docking point on the surface of a cell. When the right molecule arrives and locks into it, the cell responds. A compound that does this is called an **agonist**, which simply means it switches the receptor on.

Most compounds in this family reach fewer receptors than retatrutide:

- Semaglutide switches on one.
- Tirzepatide switches on two.
- Retatrutide switches on three.

That is why the research papers call it a **triple agonist**. The three receptors are named after the natural hormones that normally use them: GLP-1, GIP and glucagon. [GLP-1, GIP and glucagon receptor targeting](https://www.australianresearchpeptides.au/articles/glp-1-gip-glucagon-receptor-targets) explains what each of those three does.

## Is It Equally Strong at All Three?

No. Retatrutide is much stronger at one of the three than at another, which is where the phrase “triple agonist” misleads.

Three receptors sounds like three equal actions. The measurements say otherwise. Retatrutide is far stronger at one of them than at another — roughly ninety times stronger at the GIP receptor than at the glucagon receptor, with GLP-1 sitting in between.

_The three receptors retatrutide acts on, ranked by how strongly it acts at each_

| Receptor | How strongly retatrutide acts there |
| --- | --- |
| GIP | Strongest |
| GLP-1 | In between |
| Glucagon | Weakest |

So counting receptors does not rank these compounds. Three weak actions are not automatically better than one strong one.

## What Have the Trials Found?

Retatrutide has been studied in people more than most compounds sold as research chemicals. Very little animal work was published; the research went into human trials early.

Published trials have looked at:

- whether it is tolerated, in healthy volunteers
- blood sugar control, in adults with type 2 diabetes
- body weight, in adults carrying excess weight
- liver fat, measured by scanning rather than by biopsy

One useful practical detail did come out of the early work: the compound stays in the body for around six days, which is why the trials gave it once a week rather than daily.

## What Is the Current State of the Evidence?

Retatrutide evidence is not one uniform record. It runs from peer-reviewed randomised trials through completed trial registrations that have reported nothing publicly. The table below keeps those states in separate columns, because a completed trial and an available result are different facts.

Counted from the registry: **eight** phase 2 or phase 3 retatrutide trials have completed. Both phase 2 trials have posted results. Of the six completed phase 3 trials, **one has a peer-reviewed publication and none has posted results on the registry itself**.

_Completed phase 2 and phase 3 retatrutide trials, with registry result state and peer-reviewed publication state shown separately_

| Registry record | Population | Phase and size | Results posted on registry | Peer-reviewed publication |
| --- | --- | --- | --- | --- |
| NCT04881760 | Obesity or overweight | Phase 2, 338 participants | Yes | New England Journal of Medicine, 2023; a liver substudy followed in Nature Medicine, 2024 |
| NCT04867785 | Type 2 diabetes | Phase 2, 281 participants | Yes | The Lancet, 2023 |
| NCT06354660 | Type 2 diabetes | Phase 3, 537 participants | No | The Lancet, 2026 |
| NCT05929066 | Obesity or overweight, with knee osteoarthritis and obstructive sleep apnoea | Phase 3, 2,335 participants | No | None listed on the registry record |
| NCT05882045 | Obesity with cardiovascular disease | Phase 3, 1,946 participants | No | None listed on the registry record |
| NCT05929079 | Type 2 diabetes with obesity or overweight | Phase 3, 1,152 participants | No | None listed on the registry record |
| NCT05931367 | Obesity or overweight with knee osteoarthritis | Phase 3, 445 participants | No | None listed on the registry record |
| NCT05936151 | Chronic kidney disease with overweight or obesity | Phase 2, 146 participants | No | A design and baseline-characteristics paper only, 2026 |

How to read the last two columns.

A trial can be completed, published and still have nothing on the registry — and it can be completed with neither. Neither column implies the other, and a company announcement is a third thing again: it is not peer review and it is not a registry posting. Every reference in this article links to the record itself so the state can be checked rather than taken on trust.

None of this is evidence about a research vial. A trial studies a pharmaceutical formulation under a protocol; the identity and purity of material supplied for laboratory research is a separate question, answered by a [batch certificate and the methods behind it](https://www.australianresearchpeptides.au/articles/peptide-testing-purity-coa).

## What Is Still Unknown?

This is the part most pages about retatrutide leave out, and it is the part that matters most when you are judging what you read elsewhere.

- **The big weight-loss trial has not been published.** It is recorded as finished, but no results have been posted and no paper has appeared. The weight-loss percentages circulating online come from company announcements, not from published trial reports.
- **Heart and kidney effects are not known.** The large trial designed to answer that is still running.
- **Nothing beyond about a year has been described** in any published trial.
- **No published head-to-head comparison exists** against tirzepatide.
- **Heart rate rose in one trial**, more so at larger amounts. It peaked partway through and then declined. What that means long term is not established.

## Is It Approved Anywhere?

No. Retatrutide is not approved by the TGA in Australia, the FDA in the United States, or the EMA in Europe.

The TGA names retatrutide specifically as an example of an unapproved peptide product, and says such products have not been assessed for safety, quality or effectiveness. [In vitro research requirements](https://www.australianresearchpeptides.au/articles/research-use-requirements) sets out what that means for a purchaser.

## What Do You Get When You Order It?

Australian Research Peptides supplies [Retatrutide](https://www.australianresearchpeptides.au/products/retatrutide) as a freeze-dried powder in a sealed vial. Every batch is HPLC tested, and the certificate is published in the [CoA library](https://www.australianresearchpeptides.au/coa). It is listed in several vial sizes — [choosing a vial size](https://www.australianresearchpeptides.au/articles/choosing-a-vial-size) covers how to compare them.

## Common Questions

### Why Are the Weight-Loss Numbers Online Not in Here?

Because they have not been published. The large weight-management trial is listed as complete, but its results have never been posted or written up in a journal. The percentages you see quoted come from company press releases. A press release is not a trial report, and this page only reports published research.

### Is Retatrutide Approved Anywhere?

No. No medicines regulator anywhere has approved it for any use. It remains an experimental compound, and the TGA lists it by name as an example of an unapproved peptide product.

### What Makes It a Triple Agonist?

It switches on three receptors instead of one or two: GLP-1, GIP and glucagon. Agonist means it switches a receptor on, and triple means it does this at three of them. It does not mean it acts equally strongly at all three, because it does not.

### Is Retatrutide the Same as Semaglutide or Tirzepatide?

No. All three are separate molecules with different sequences. The clearest difference is how many receptors each one reaches: semaglutide one, tirzepatide two, retatrutide three. Being different is not the same as being better, and no published trial has compared retatrutide directly against tirzepatide.

The compound behind that trial record is catalogued by Australian Research Peptides in three vial strengths, all in stock and each with the laboratory's report published, and ships from Sydney as research material rather than as any of the therapies the trials above were testing.

## References

1. [Coskun T, Urva S, Roell WC, et al. Cell Metabolism 2022;34(9):1234-1247 (PMID 35985340)](https://europepmc.org/article/MED/35985340)
2. [Jastreboff AM, Kaplan LM, Frias JP, et al. New England Journal of Medicine 2023;389(6):514-526 (PMID 37366315)](https://pubmed.ncbi.nlm.nih.gov/37366315/)
3. [Rosenstock J, Frias J, Jastreboff AM, et al. The Lancet 2023;402:529-544 (PMID 37385280)](https://pubmed.ncbi.nlm.nih.gov/37385280/)
4. [Sanyal AJ, Kaplan LM, Frias JP, et al. Nature Medicine 2024;30:2037-2048 (PMID 38858523, PMCID PMC11271400)](https://pubmed.ncbi.nlm.nih.gov/38858523/)
5. [ClinicalTrials.gov — LY3437943 trial registry records](https://clinicaltrials.gov/search?intr=LY3437943)
6. [Eli Lilly — TRIUMPH-1 phase 3 topline results, 21 May 2026](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html)
7. [Bajaj HS, et al. Retatrutide in people with type 2 diabetes — phase 3. The Lancet 2026 (PMID 42250575)](https://pubmed.ncbi.nlm.nih.gov/42250575/)
8. [Heerspink HJL, et al. TRANSCEND-CKD: rationale, design and baseline characteristics. Nephrology Dialysis Transplantation 2026 (PMID 41160422)](https://pubmed.ncbi.nlm.nih.gov/41160422/)
9. [ClinicalTrials.gov — NCT05929066 (TRIUMPH-1) registry record](https://clinicaltrials.gov/study/NCT05929066)

## Related guides

- [Tesamorelin: What It Is and Who the Trials Studied](https://www.australianresearchpeptides.au/articles/tesamorelin-ghrh-analogue-research)
- [GHK-Cu: What It Is and Why It Carries Copper](https://www.australianresearchpeptides.au/articles/ghk-cu-copper-peptide-mechanism)

## Related compounds

- [Retatrutide](https://www.australianresearchpeptides.au/products/retatrutide)

---

_Plain-text version of https://www.australianresearchpeptides.au/articles/retatrutide-mechanism-and-trial-record. The web page is the canonical version of this article._

_All products supplied by Australian Research Peptides are for in vitro research purposes only._